BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. Inflamm Bowel Dis. 2017;23:833-839. [PMID: 28328624 DOI: 10.1097/mib.0000000000001074] [Cited by in Crossref: 49] [Cited by in F6Publishing: 12] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Choi DK, Puangampai A, Rubin DT. Prior Authorization for Ustekinumab Dose Escalation Negatively Affects Outcomes in Patients With Inflammatory Bowel Disease. Ann Pharmacother 2022;:10600280221080986. [PMID: 35300521 DOI: 10.1177/10600280221080986] [Reference Citation Analysis]
2 Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, Löwenberg M, Dijkstra G, Oldenburg B, de Boer NKH, van der Marel S, Bodelier AGL, Jansen JM, Haans JJL, Theeuwen R, de Jong D, Pierik MJ, Hoentjen F. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis 2020;14:33-45. [PMID: 31219157 DOI: 10.1093/ecco-jcc/jjz119] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 24.5] [Reference Citation Analysis]
3 Bar-Gil Shitrit A, Ben-Ya'acov A, Siterman M, Waterman M, Hirsh A, Schwartz D, Zittan E, Adler Y, Koslowsky B, Avni-Biron I, Chowers Y, Ron Y, Israeli E, Ungar B, Yanai H, Maharshak N, Ben-Horin S, Eliakim R, Dotan I, Goldin E, Kopylov U. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study. United European Gastroenterol J 2020;8:418-24. [PMID: 32213026 DOI: 10.1177/2050640620902956] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
4 Bermejo F, Guerra I, Algaba A, López-Sanromán A. Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease. Drugs 2018;78:1-18. [PMID: 29139091 DOI: 10.1007/s40265-017-0842-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
5 Ahmed Z, Venkata K, Zhang N, Malik TA. Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center. Gastroenterology Res 2019;12:245-51. [PMID: 31636774 DOI: 10.14740/gr1194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Rahme E, Nedjar H, Afif W. Cost of Refractory Crohn's Disease Before and After Ustekinumab Utilization. J Can Assoc Gastroenterol 2020;3:257-65. [PMID: 33241178 DOI: 10.1093/jcag/gwz025] [Reference Citation Analysis]
7 Annese V, Nathwani R, Alkhatry M, Al-Rifai A, Al Awadhi S, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Taha MS, Limdi JK. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol 2021;14:17562848211065329. [PMID: 34987611 DOI: 10.1177/17562848211065329] [Reference Citation Analysis]
8 Inoue A, Bartlett DJ, Shahraki N, Sheedy SP, Heiken JP, Voss BA, Fidler JL, Tootooni MS, Sir MY, Pasupathy K, Baker ME, Rieder F, Lightner AL, Deepak P, Bruining DH, Fletcher JG. Predicting Risk of Surgery in Patients With Small Bowel Crohn's Disease Strictures Using Computed Tomography and Magnetic Resonance Enterography. Inflamm Bowel Dis 2022:izab332. [PMID: 35032168 DOI: 10.1093/ibd/izab332] [Reference Citation Analysis]
9 Lenti MV, Dolby V, Clark T, Hall V, Tattersall S, Fairhurst F, Kenneth C, Walker R, Kemp K, Borg-Bartolo S, Limdi JK, Taylor J, Townsend T, Subramanian S, Storey D, Assadsangabi A, Stansfield C, Smith P, Byrne D, De Silvestri A, Selinger CP. A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Aliment Pharmacol Ther 2021. [PMID: 34935160 DOI: 10.1111/apt.16742] [Reference Citation Analysis]
10 Rentsch C, Headon B, Ward MG, Gibson PR. Inadequate storage of subcutaneous biological agents by patients with inflammatory bowel disease: Another factor driving loss of response? J Gastroenterol Hepatol 2018;33:10-1. [PMID: 29284080 DOI: 10.1111/jgh.14001] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn's disease: optimising the old and maximising the new. F1000Res 2019;8:F1000 Faculty Rev-1210. [PMID: 31448080 DOI: 10.12688/f1000research.18902.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
12 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Tamilarasan AG, Cunningham G, Irving PM, Samaan MA. Recent advances in monoclonal antibody therapy in IBD: practical issues. Frontline Gastroenterol 2019;10:409-16. [PMID: 31656567 DOI: 10.1136/flgastro-2018-101054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Atreya R, Bojarski C, Kühl AA, Trajanoski Z, Neurath MF, Siegmund B. Ileal and colonic Crohn'´s disease: Ddoes location makes a difference in therapy efficacy? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100097] [Reference Citation Analysis]
15 Yao JY, Zhang M, Wang W, Peng X, Zhao JZ, Liu T, Li ZW, Sun HT, Hu P, Zhi M. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study. BMC Gastroenterol 2021;21:380. [PMID: 34663208 DOI: 10.1186/s12876-021-01946-8] [Reference Citation Analysis]
16 Cassinotti A, Batticciotto A, Parravicini M, Lombardo M, Radice P, Cortelezzi CC, Segato S, Zanzi F, Cappelli A, Segato S. Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications. Therap Adv Gastroenterol 2022;15:17562848221085889. [PMID: 35340755 DOI: 10.1177/17562848221085889] [Reference Citation Analysis]
17 Scribano ML, Aratari A, Neri B, Bezzio C, Balestrieri P, Baccolini V, Falasco G, Camastra C, Pantanella P, Monterubbianesi R, Tullio A, Saibeni S, Papi C, Biancone L, Cosintino R, Faggiani R. Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy. Therap Adv Gastroenterol 2022;15:175628482110724. [DOI: 10.1177/17562848211072412] [Reference Citation Analysis]
18 Harris RJ, McDonnell M, Young D, Bettey M, Downey L, Pigott L, Felwick R, Gwiggner M, Cummings JRF. Early real-world effectiveness of ustekinumab for Crohn's disease. Frontline Gastroenterol 2020;11:111-6. [PMID: 32133109 DOI: 10.1136/flgastro-2019-101237] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
19 Gutiérrez A, Rodríguez-Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne) 2021;8:640813. [PMID: 33585530 DOI: 10.3389/fmed.2021.640813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kelm M, Germer CT, Schlegel N, Flemming S. The Revival of Surgery in Crohn's Disease-Early Intestinal Resection as a Reasonable Alternative in Localized Ileitis. Biomedicines 2021;9:1317. [PMID: 34680434 DOI: 10.3390/biomedicines9101317] [Reference Citation Analysis]
21 Kotze PG, Ma C, Almutairdi A, Panaccione R. Clinical utility of ustekinumab in Crohn's disease. J Inflamm Res. 2018;11:35-47. [PMID: 29445293 DOI: 10.2147/jir.s157358] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
22 Yang H, Li B, Guo Q, Tang J, Peng B, Ding N, Li M, Yang Q, Huang Z, Diao N, Zhu X, Deng J, Guo H, Hu P, Chao K, Gao X. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases. Aliment Pharmacol Ther 2022. [PMID: 35141914 DOI: 10.1111/apt.16802] [Reference Citation Analysis]
23 Hoffmann P, Krisam J, Wehling C, Kloeters-Plachky P, Leopold Y, Belling N, Gauss A. Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease. World J Gastroenterol 2019; 25(31): 4481-4492 [PMID: 31496626 DOI: 10.3748/wjg.v25.i31.4481] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]